Arcoxia is one option. This drug belongs to a group of medicines called cyclooxygenase-2 (COX-2). Of course, osteoarthritis patients should know more about this medication before deciding that ...

said Friday it expects the Food and Drug Administration to rule by April on its arthritis drug Arcoxia, a cousin of Vioxx, the painkiller that's no longer on the market. The company has filed ...

Mar. 23 -- FRIDAY, April 27 (HealthDay News) -- The U.S. Food and Drug Administration on Friday turned down Merck & Co.'s request to market Arcoxia, a successor to its banned arthritis drug Vioxx.

NEW YORK (CNNMoney.com) -- The FDA shot down Merck's application for an arthritis painkiller that has been widely criticized for its resemblance to Vioxx. Arcoxia is already available in 63 ...

Merck, for its part, is betting that the $500 million already invested in Arcoxia can still earn some kind of payback if the FDA will approve the cox-2 inhibitor for a segment of the market. And … ...

Merck today withdrew its application with the Food and Drug Administration for Arcoxia, its next-generation painkiller. Many analysts had been expecting the drug to help Merck win a long-standing ...

The FDA has issued a non-approvable letter for Merck’s Arcoxia. Merck was seeking approval of the Vioxx-like drug as a treatment for osteoarthritis. Vioxx was pulled off the market in September 2004 ...

NEW YORK (Reuters) - Merck & Co. said on Friday that U.S. regulators have rejected its experimental arthritis drug Arcoxia, the drugmaker's follow-up to Vioxx, saying it could not be approved ...

Merck suffered a bitter loss on Thursday as a US regulatory panel recommended that its long-studied painkiller Arcoxia, the successor to its withdrawn drug Vioxx, should not be approved.

FDA whistle-blower David Graham has blasted Merck's Arcoxia, a new painkiller designed to replace Vioxx, as unsafe. "The FDA, academia, and the medical research enterprise are once again faced ...

The move was widely expected, after a panel of FDA advisers two weeks ago voted 20-1 against approving the drug, Arcoxia. Arcoxia is in the class of anti-inflammatory drugs called COX-2 inhibitors ...

BOSTON (MarketWatch) -- The Food and Drug Administration on Friday rejected Merck & Co.'s application for the pain reliever Arcoxia, the company's follow-up to Vioxx.